Teclistamab in combination with daratumumab and lenalidomide in multiple myeloma (majesTEC-2 study)
Searle, Emily Quach, H Wong, S Costa, L Hulin, C Janowski, W Berdeja, J Anguille, S Matous, J Touzeau, C
Searle, Emily
Quach, H
Wong, S
Costa, L
Hulin, C
Janowski, W
Berdeja, J
Anguille, S
Matous, J
Touzeau, C
Citations
Altmetric:
Abstract
Authors
Searle, Emily
Quach, H
Wong, S
Costa, L
Hulin, C
Janowski, W
Berdeja, J
Anguille, S
Matous, J
Touzeau, C
Michallet, AS
Husnik, M
Vishwamitra, D
Niu, Z
Larsen, J
Chen, LL
Goldberg, J
Popat, R
Spencer, A
Quach, H
Wong, S
Costa, L
Hulin, C
Janowski, W
Berdeja, J
Anguille, S
Matous, J
Touzeau, C
Michallet, AS
Husnik, M
Vishwamitra, D
Niu, Z
Larsen, J
Chen, LL
Goldberg, J
Popat, R
Spencer, A
Affiliation
University Of Manchester And The Christie NHS Foundation Trust, Manchester, UK
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Searle E, Quach H, Wong S, Costa L, Hulin C, Janowski W, et al. Teclistamab in combination with daratumumab and lenalidomide in multiple myeloma (MajesTEC-2 study). British journal of haematology. 2023 APR;201:74-. PubMed PMID: WOS:001049283000119. English.